Indication, complication, and prognosis of fiberoptic bronchoscopy guided percutaneous dilatation tracheostomy opening in respiratory intensive care unit: a retrospective study.

OBJECTIVE: Percutaneous dilatational tracheostomy (PDT) is a bedside applicable procedure in intensive care unit patients requiring long-term mechanical ventilation. Fiber optic bronchoscopy (FOB) makes it easier and reduces complications. Our study aimed to evaluate the indications, complications, and prognosis of PDTs performed with FOB. PATIENTS AND METHODS: Our study included 114 patients undergoing PDT through FOB-guided Griggs method in the Respiratory Intensive Care Unit between January 01, 2018, and January 31, 2023. RESULTS: Among the patients undergoing PDT with FOB, 81 (71.1%) were male. The mean age was 62.1±11.5. The median Glasgow Coma Scale (GCS) score was 9, the median Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score was 19, and the median Sequential Organ Failure Assessment (SOFA) score was 8. Tracheostomy was opened for prolonged mechanical-ventilator requirement in 80 patients (70.2%), to protect the airway in 19 (16.7%), and for poor neurologic status in 15 patients (13.2%). Complications during the procedure included hypoxemia in 3 patients (2.6%), minor bleeding in 3 patients (2.6%), perforation of the FOB in one patient (0.8%), and perforation of the intubation tube cuff in one patient (0.8%). 79 patients (69.3%) were discharged, and 35 (30.7%) were exited. There was a significant difference between the GCS, APACHE-II, and SOFA scores of the patients discharged and those who exited (p < 0.001). CONCLUSIONS: FOB-guided PDT application should be encouraged as it reduces complications but it is still limited because it requires experienced specialists and equipment for a standard approach.

Evaluation of carotid intima-media thickness with vascular endothelial growth factor and malondialdehyde levels in patients with sarcoidosis.

PURPOSE: To assess the impact of sarcoidosis on endothelial function by measuring carotid intima-media thickness (CIMT) and serum levels of malondialdehyde and vascular endothelial growth factor (VEGF). MATERIALS AND METHODS: We prospectively analyzed 41 patients with sarcoidosis (9 men, 32 women) with a mean age of 44.9±10.2 (SD) years and 34 healthy subjects (9 men, 24 women) with a mean age of 37.26±8.9 (SD) years who served as a control group. Sarcoidosis patients receiving steroids were included in Group 1 while those not under steroid treatment were included in Group 2. CIMT measurements were performed using B-mode ultrasound. Malondialdehyde and VEGF serum levels were obtained in all sarcoidosis patients and control subjects. RESULTS: Both right and left CIMT was significantly higher in Group 1 and Group 2 than in control subjects. Serum levels of malondialdehyde and VEGF in Group 1 and Group 2 were significantly higher than in healthy subjects. No differences in CIMT, malondialdehyde and VEGF were found between Group 1 and Group 2. CONCLUSION: Sarcoidosis results in increased CIMT, VEGF and malondialdehyde serum levels. However, there was no difference in terms of CIMT, VEGF and malondialdehyde levels between sarcoidosis patients with or without steroid treatment, suggesting that new treatment strategies for sarcoidosis vascular involvement should consider this result.